
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 69,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
我们正在追踪 Novo Nordisk 的市场扩张
最近 90 天内有 315 个信号。
Novo Nordisk 的国际扩张与竞争对手的对比情况
条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
Novo Nordisk你 | 0 | 0 | — | 0 | 0 |
Supervisor, Business Intelligence
查看职位Taipei, Taipei City, Taiwan · 今天
Senior IT/OT Solution Architect - API Expansion
查看职位Kalundborg, Region Zealand, Denmark · 今天
Pharma Field Sales - Cardiometabolic Care Specialist I - P Bakersfield North California
查看职位Bakersfield, CA · 5天前
Talk to a doctor
已结束Talk to a doctor
已结束Talk to a doctor
已结束巴西制药公司EMS将于6月15日推出国产司美格鲁肽,每支售价452雷亚尔,比Ozempic等进口产品便宜30%,使肥胖治疗更易获得。
康霈生技于ADA 2026发表CBL-514动物实验数据,显示与GLP-1/RA类药物并用可将复胖率降低2.7倍,肝脏脂肪额外减少106.7%。
诺和诺德在中国推出诺泽优(帕西生长激素),为2.5岁以上生长激素缺乏儿童提供每周一次治疗选择,采用创新脂肪酸技术及零PEG配方。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Novo Nordisk 的业务、市场和增长信号的快速解答。
